Lower urinary tract symptoms in Parkinson's disease: Prevalence, aetiology and management

Parkinsonism and Related Disorders

Volumn 35, Issue , 2017, Pages 8-16

  McDonald, Claire ^a,c   Winge, Kristian ^b   Burn, David J ^a,c  

^a NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b BISPEBJERG HOSPITAL   (Denmark)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Incontinence; Lower urinary tract; Over active bladder; Parkinson's disease

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BOTULINUM TOXIN; BROMOCRIPTINE; DESMOPRESSIN; MIRABEGRON; MUSCARINIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT;

ANTERIOR CINGULATE; AUTONOMIC NERVOUS SYSTEM; BASAL GANGLION; CLINICAL TRIAL (TOPIC); CONSERVATIVE TREATMENT; DOPAMINE METABOLISM; HUMAN; INSULA; LOWER URINARY TRACT SYMPTOM; MICTURITION; NONHUMAN; OVERACTIVE BLADDER; PARKINSON DISEASE; PATHOGENESIS; PREFRONTAL CORTEX; PREVALENCE; PROSTATECTOMY; REVIEW; URODYNAMICS; DISEASE MANAGEMENT; URINE INCONTINENCE;

DISEASE MANAGEMENT; DOPAMINE AGENTS; HUMANS; LOWER URINARY TRACT SYMPTOMS; PARKINSON DISEASE; PREVALENCE; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 85006782903     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2016.10.024     Document Type: Review

References (102)

1. [1] Parkinson, J., An essay on the shaking palsy. J. Neuropsychiatry Clin. Neurosci. 2002:14 (1817), 223–236, 10.1176/jnp.14.2.223.
2. [2] Cheon, S.M., Ha, M.S., Park, M.J., Kim, J.W., Nonmotor symptoms of parkinson's disease: prevalence and awareness of patients and families. Park. Relat. Disord. 14 (2008), 286–290, 10.1016/j.parkreldis.2007.09.002.
3. [3] Araki, I., Kuno, S., Assessment of voiding dysfunction in parkinson's disease by the international prostate symptom score. J. Neurol. Neurosurg. Psychiatry 68 (2000), 429–433.
4. [4] Sakakibara, R., Shinotoh, H., Uchiyama, T., Sakuma, M., Kashiwado, M., Yoshiyama, M., Hattori, T., Questionnaire-based assessment of pelvic organ dysfunction in parkinson's disease. Aut. Neurosci. Basic Clin. 92 (2001), 76–85, 10.1016/S1566-0702(01)00295-8.
5. [5] Rahman, S., Griffin, H.J., Quinn, N.P., Jahanshahi, M., Quality of life in parkinson's disease: the relative importance of the symptoms. Mov. Disord. Off. J. Mov. Disord. Soc. 23 (2008), 1428–1434, 10.1002/mds.21667.
6. [6] Balash, Y., Peretz, C., Leibovich, G., Herman, T., Hausdorff, J.M., Giladi, N., Falls in outpatients with parkinson's disease: frequency, impact and identifying factors. J. Neurol. 252 (2005), 1310–1315, 10.1007/s00415-005-0855-3.
7. [7] Campos-Sousa, R.N., Quagliato, E., da Silva, B.B., de Carvalho, R.M. Jr., Ribeiro, S.C., de Carvalho, D.F., Urinary symptoms in parkinson's disease: prevalence and associated factors. Arq. Neuropsiquiatr. 61 (2003), 359–363.
8. [8] Hattori, T., Yasuda, K., Kita, K., Hirayama, K., Voiding dysfunction in parkinson's disease. Jpn. J. Psychiatry Neurol. 46 (1992), 181–186.
9. [9] Hobson, P., Islam, W., Roberts, S., Adhiyman, V., Meara, J., The risk of bladder and autonomic dysfunction in a community cohort of parkinson's disease patients and normal controls. Park. Relat. Disord. 10 (2003), 67–71.
10. [10] Zhang, L.M., Zhang, X.P., Investigation of urination disorder in parkinson's disease. Chin. Med. J. 128 (2015), 2906–2912, 10.4103/0366-6999.168049.
11. [11] Liu, Z., Uchiyama, T., Sakakibara, R., Yamamoto, T., Underactive and overactive bladders are related to motor function and quality of life in parkinson's disease. Int. Urol. Nephrol. 47 (2015), 751–757, 10.1007/s11255-015-0951-y.
12. [12] Winge, K., Skau, A.M., Stimpel, H., Nielsen, K.K., Werdelin, L., Prevalence of bladder dysfunction in parkinsons disease. Neurourol. Urodyn. 25 (2006), 116–122, 10.1002/nau.20193.
13. [13] Kapoor, S., Bourdoumis, A., Mambu, L., Barua, J., Effective management of lower urinary tract dysfunction in idiopathic parkinson's disease. Int. J. Urol. 20 (2013), 79–84, 10.1111/j.1442-2042.2012.03220.x.
14. [14] Ragab, M.M., Mohammed, E.S., Idiopathic parkinson's disease patients at the urologic clinic. Neurourol. Urodyn. 30 (2011), 1258–1261, 10.1002/nau.20983.
15. [15] Barry, M.J., Fowler, F.J. Jr., O'Leary, M.P., Bruskewitz, R.C., Holtgrewe, H.L., Mebust, W.K., Cockett, A.T., The american urological association symptom index for benign prostatic hyperplasia. The measurement committee of the american urological association. J. Urol. 148 (1992), 1549–1557 discussion 1564.
16. [16] Hansen, B.J., Flyger, H., Brasso, K., Schou, J., Nordling, J., Andersen, J.T., Mortensenm, S., Meyhoff, H.H., Walter, S., Hald, T., Validation of the self-administered danish prostatic symptom score (dan-pss-1) system for use in benign prostatic hyperplasia. Br. J. Urol. 76 (1995), 451–458.
17. [17] Chaudhuri, K.R., Martinez-Martin, P., Brown, R.G., Sethi, K., Stocchi, F., Odin, P., Ondo, W., Abe, K., Macphee, G., Macmahon, D., Barone, P., Rabey, M., Forbes, A., Breen, K., Tluk, S., Naidu, Y., Olanow, W., Williams, A.J., Thomas, S., Rye, D., Tsuboi, Y., Hand, A., Schapira, A.H., The metric properties of a novel non-motor symptoms scale for parkinson's disease: results from an international pilot study. Mov. Disord. Off. J. Mov. Disord. Soc. 22 (2007), 1901–1911, 10.1002/mds.21596.
18. [18] Chaudhuri, K.R., Martinez-Martin, P., Quantitation of non-motor symptoms in parkinson's disease. Eur. J. Neurol. Off. J. Eur. Fed. Neurol. Soc. 15:2 (2008), 2–7, 10.1111/j.1468-1331.2008.02212.x.
19. [19] Barone, P., Antonini, A., Colosimo, C., Marconi, R., Morgante, L., Avarello, T.P., Bottacchi, E., Cannas, A., Ceravolo, G., Ceravolo, R., Cicarelli, G., Gaglio, R.M., Giglia, R.M., Iemolo, F., Manfredi, M., Meco, G., Nicoletti, A., Pederzoli, M., Petrone, A., Pisani, A., Pontieri, F.E., Quatrale, R., Ramat, S., Scala, R., Volpe, G., Zappulla, S., Bentivoglio, A.R., Stocchi, F., Trianni, G., Dotto, P.D., group Ps, The priamo study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in parkinson's disease. Mov. Disord. Off. J. Mov. Disord. Soc. 24 (2009), 1641–1649, 10.1002/mds.22643.
20. [20] Uchiyama, T., Sakakibara, R., Yamamoto, T., Ito, T., Yamaguchi, C., Awa, Y., Yanagisawa, M., Higuchi, Y., Sato, Y., Ichikawa, T., Yamanishi, T., Hattori, T., Kuwabara, S., Urinary dysfunction in early and untreated parkinson's disease. J. Neurol. Neurosurg. Psychiatry 82 (2011), 1382–1386, 10.1136/jnnp.2011.241075.
21. [21] Abrams, P., Cardozo, L., Fall, M., Griffiths, D., Rosier, P., Ulmsten, U., Van Kerrebroeck, P., Victor, A., Wein, A., Standardisation Sub-Committee of the International Continence S, The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the international continence society. Urology 61 (2003), 37–49.
22. [22] Sakakibara, R., Hattori, T., Uchiyama, T., Yamanishi, T., Urinary function in elderly people with and without leukoaraiosis: relation to cognitive and gait function. J. Neurol. Neurosurg. Psychiatry 67 (1999), 658–660, 10.1136/jnnp.67.5.658.
23. [23] Sakakibara, R., Panicker, J., Fowler, C.J., Tateno, F., Kishi, M., Tsuyuzaki, Y., Ogawa, E., Uchiyama, T., Yamamoto, T., Vascular incontinence: incontinence in the elderly due to ischemic white matter changes. Neurol. Int., 4, 2012, e13, 10.4081/ni.2012.e13.
24. [24] Khoo, T.K., Yarnall, A.J., Duncan, G.W., Coleman, S., O'Brien, J.T., Brooks, D.J., Barker, R.A., Burn, D.J., The spectrum of nonmotor symptoms in early parkinson disease. Neurology 80 (2013), 276–281, 10.1212/WNL.0b013e31827deb74.
25. [25] Wenning, G.K., Scherfler, C., Granata, R., Bosch, S., Verny, M., Chaudhuri, K.R., Jellinger, K., Poewe, W., Litvan, I., Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J. Neurol. Neurosurg. Psychiatry 67 (1999), 620–623.
26. [26] Rana, A.Q., Vaid, H., Akhter, M.R., Awan, N.Y., Fattah, A., Cader, M.H., Hafez, K., Rana, M.A., Yousuf, M.S., Prevalence of nocturia in parkinson's disease patients from various ethnicities. Neurol. Res. 36 (2014), 234–238, 10.1179/1743132813Y.0000000264.
27. [27] Tsujimura, A., Yamamoto, Y., Sakoda, S., Okuda, H., Yamamoto, K., Fukuhara, S., Yoshioka, I., Kiuchi, H., Takao, T., Miyagawa, Y., Nonomura, N., Finger taps and constipation are closely related to symptoms of overactive bladder in male patients with parkinson's disease. Int. J. Urol. 21 (2014), 69–73, 10.1111/iju.12186.
28. [28] Lemack, G.E., Dewey, R.B. Jr., Roehrborn, C.G., O'Suilleabhain, P.E., Zimmern, P.E., Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate parkinson's disease. Urology 56 (2000), 250–254.
29. [29] Winge, K., Nielsen, K.K., Bladder dysfunction in advanced parkinson's disease. Neurourol. Urodyn. 31 (2012), 1279–1283, 10.1002/nau.22237.
30. [30] Wullner, U., Schmitz-Hubsch, T., Antony, G., Fimmers, R., Spottke, A., Oertel, W.H., Deuschl, G., Klockgether, T., Eggert, K., e.V KNP, Autonomic dysfunction in 3414 parkinson's disease patients enrolled in the german network on parkinson's disease (knp e.V.): the effect of ageing. Eur. J. Neurol. Off. J. Eur. Fed. Neurol. Soc. 14 (2007), 1405–1408, 10.1111/j.1468-1331.2007.01982.x.
31. [31] Robinson, J.P., Bradway, C.W., Bunting-Perry, L., Avi-Itzhak, T., Mangino, M., Chittams, J., Duda, J.E., Lower urinary tract symptoms in men with parkinson disease. J. Neurosci. Nurs. J. Am. Assoc. Neurosci. Nurses 45 (2013), 382–392, 10.1097/JNN.0b013e3182a3cf67 quiz E381-382.
32. [32] Bonnet, A.M., Pichon, J., Vidailhet, M., Gouider-Khouja, N., Robain, G., Perrigot, M., Agid, Y., Urinary disturbances in striatonigral degeneration and parkinson's disease: clinical and urodynamic aspects. Mov. Disord. Off. J. Mov. Disord. Soc. 12 (1997), 509–513, 10.1002/mds.870120406.
33. [33] Picillo, M., Erro, R., Amboni, M., Longo, K., Vitale, C., Moccia, M., Pierro, A., Scannapieco, S., Santangelo, G., Spina, E., Orefice, G., Barone, P., Pellecchia, M.T., Gender differences in non-motor symptoms in early parkinson's disease: a 2-years follow-up study on previously untreated patients. Park. Relat. Disord. 20 (2014), 850–854, 10.1016/j.parkreldis.2014.04.023.
34. [34] Ou, R., Yang, J., Cao, B., Wei, Q., Chen, K., Chen, X., Zhao, B., Wu, Y., Song, W., Shang, H., Progression of non-motor symptoms in parkinson's disease among different age populations: a two-year follow-up study. J. Neurol. Sci. 360 (2016), 72–77, 10.1016/j.jns.2015.11.047.
35. [35] Campos-Sousa, R.N., Quagliato, E.M., Almeida, K.J., Castro, I.A., Campelo, V., Urinary dysfunction with detrusor hyperactivity in women with parkinson's disease cannot be blamed as a factor of worsening motor performance. Arq. Neuropsiquiatr. 71 (2013), 591–595, 10.1590/0004-282X20130101.
36. [36] Sakakibara, R., Hattori, T., Uchiyama, T., Yamanishi, T., Videourodynamic and sphincter motor unit potential analyses in parkinson's disease and multiple system atrophy. J. Neurol. Neurosurg. Psychiatry 71 (2001), 600–606, 10.1136/jnnp.71.5.600.
37. [37] Araki, I., Kitahara, M., Oida, T., Kuno, S., Voiding dysfunction and parkinson's disease: urodynamic abnormalities and urinary symptoms. J. Urol. 164 (2000), 1640–1643.
38. [38] Stocchi, F., Carbone, A., Inghilleri, M., Monge, A., Ruggieri, S., Berardelli, A., Manfredi, M., Urodynamic and neurophysiological evaluation in parkinson's disease and multiple system atrophy. J. Neurol. Neurosurg. Psychiatry 62 (1997), 507–511.
39. [39] Defreitas, G.A., Lemack, G.E., Zimmern, P.E., Dewey, R.B., Roehrborn, C.G., O'Suilleabhain, P.E., Distinguishing neurogenic from non-neurogenic detrusor overactivity: a urodynamic assessment of lower urinary tract symptoms in patients with and without parkinson's disease. Urology 62 (2003), 651–655, 10.1016/S0090-4295(03)00507-7.
40. [40] Terayama, K., Sakakibara, R., Ogawa, A., Haruta, H., Akiba, T., Nagao, T., Takahashi, O., Sugiyama, M., Tateno, A., Tateno, F., Yano, M., Kishi, M., Tsuyusaki, Y., Uchiyama, T., Yamamoto, T., Weak detrusor contractility correlates with motor disorders in parkinson's disease. Mov. Disord. Off. J. Mov. Disord. Soc. 27 (2012), 1775–1780, 10.1002/mds.25225.
41. [41] Sakakibara, R., Tateno, F., Kishi, M., Tsuyuzaki, Y., Uchiyama, T., Yamamoto, T., Pathophysiology of bladder dysfunction in parkinson's disease. Neurobiol. Dis. 46 (2012), 565–571, 10.1016/j.nbd.2011.10.002.
42. [42] Fowler, C.J., Griffiths, D., de Groat, W.C., The neural control of micturition. Nat. Rev. Neurosci. 9 (2008), 453–466, 10.1038/nrn2401.
43. [43] Fowler, C.J., Update on the neurology of parkinson's disease. Neurourol. Urodyn. 26 (2007), 103–109, 10.1002/nau.20371.
44. [44] Griffiths, D.J., Fowler, C.J., The micturition switch and its forebrain influences. Acta Physiol. 207 (2013), 93–109, 10.1111/apha.12019.
45. [45] Goedert, M., Spillantini, M.G., Del Tredici, K., Braak, H., 100 years of lewy pathology. Nat. Rev. Neurol. 9 (2013), 13–24, 10.1038/nrneurol.2012.242.
46. [46] Sakakibara, R., Uchiyama, T., Yamanishi, T., Kishi, M., Genitourinary dysfunction in parkinson's disease. Mov. Disord. Off. J. Mov. Disord. Soc. 25 (2010), 2–12, 10.1002/mds.22519.
47. [47] Yoshimura, N., Mizuta, E., Yoshida, O., Kuno, S., Therapeutic effects of dopamine d1/d2receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys. J. Pharmacol. Exp. Ther. 286 (1998), 228–233.
48. [48] Albanese, A., Jenner, P., Marsden, C.D., Stephenson, J.D., Bladder hyperreflexia induced in marmosets by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurosci. Lett. 87 (1988), 46–50.
49. [49] Yoshimura, N., Kuno, S., Chancellor, M.B., De Groat, W.C., Seki, S., Dopaminergic mechanisms underlying bladder hyperactivity in rats with a unilateral 6-hydroxydopamine (6-ohda) lesion of the nigrostriatal pathway. Br. J. Pharmacol. 139 (2003), 1425–1432, 10.1038/sj.bjp.0705388.
50. [50] Kontani, H., Inoue, T., Sakai, T., Dopamine receptor subtypes that induce hyperactive urinary bladder response in anesthetized rats. Jpn. J. Pharmacol. 54 (1990), 482–486.
51. [51] Seki, S., Igawa, Y., Kaidoh, K., Ishizuka, O., Nishizawa, O., Andersson, K.E., Role of dopamine d1 and d2 receptors in the micturition reflex in conscious rats. Neurourol. Urodyn. 20 (2001), 105–113.
52. [52] Yokoyama, O., Yoshiyama, M., Namiki, M., de Groat, W.C., Glutamatergic and dopaminergic contributions to rat bladder hyperactivity after cerebral artery occlusion. Am. J. Physiol. 276 (1999), R935–R942.
53. [53] Sakakibara, R., Shinotoh, H., Uchiyama, T., Yoshiyama, M., Hattori, T., Yamanishi, T., Spect imaging of the dopamine transporter with [(123)i]-beta-cit reveals marked decline of nigrostriatal dopaminergic function in parkinson's disease with urinary dysfunction. J. Neurol. Sci. 187 (2001), 55–59.
54. [54] Winge, K., Friberg, L., Werdelin, L., Nielsen, K.K., Stimpel, H., Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in parkinson's disease. Eur. J. Neurol. Off. J. Eur. Fed. Neurol. Soc. 12 (2005), 842–850, 10.1111/j.1468-1331.2005.01087.x.
55. [55] Winge, K., Nielsen, K.K., Stimpel, H., Lokkegaard, A., Jensen, S.R., Werdelin, L., Lower urinary tract symptoms and bladder control in advanced parkinson's disease: effects of deep brain stimulation in the subthalamic nucleus. Mov. Disord. Off. J. Mov. Disord. Soc. 22 (2007), 220–225, 10.1002/mds.21253.
56. [56] Nazzaro, J.M., Pahwa, R., Lyons, K.E., The impact of bilateral subthalamic stimulation on non-motor symptoms of parkinson's disease. Park. Relat. Disord. 17 (2011), 606–609, 10.1016/j.parkreldis.2011.05.009.
57. [57] Pietraszko, W., Furgala, A., Gorecka-Mazur, A., Thor, P., Moskala, M., Polak, J., Surowka, A.D., Krygowska-Wajs, A., Efficacy of deep brain stimulation of the subthalamic nucleus on autonomic dysfunction in patients with parkinson's disease. Folia Med. Cracov 53 (2013), 15–22.
58. [58] Mordasini, L., Kessler, T.M., Kiss, B., Schupbach, M., Pollo, C., Kaelin-Lang, A., Bladder function in patients with dystonia undergoing deep brain stimulation. Park. Relat. Disord. 20 (2014), 1015–1017, 10.1016/j.parkreldis.2014.05.016.
59. [59] Herzog, J., Weiss, P.H., Assmus, A., Wefer, B., Seif, C., Braun, P.M., Herzog, H., Volkmann, J., Deuschl, G., Fink, G.R., Subthalamic stimulation modulates cortical control of urinary bladder in parkinson's disease. Brain A J. Neurol. 129 (2006), 3366–3375, 10.1093/brain/awl302.
60. [60] Seif, C., Herzog, J., van der Horst, C., Schrader, B., Volkmann, J., Deuschl, G., Juenemann, K.P., Braun, P.M., Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann. Neurol. 55 (2004), 118–120, 10.1002/ana.10806.
61. [61] Finazzi-Agro, E., Peppe, A., D'Amico, A., Petta, F., Mazzone, P., Stanzione, P., Micali, F., Caltagirone, C., Effects of subthalamic nucleus stimulation on urodynamic findings in patients with parkinson's disease. J. Urol. 169 (2003), 1388–1391, 10.1097/01.ju.0000055520.88377.dc.
62. [62] Kitta, T., Mitsui, T., Kanno, Y., Chiba, H., Moriya, K., Shinohara, N., Brain-bladder control network: the unsolved 21st century urological mystery. Int. J. Urol. 22 (2015), 342–348, 10.1111/iju.12721.
63. [63] Sakakibara, R., Uchida, Y., Ishii, K., Kazui, H., Hashimoto, M., Ishikawa, M., Yuasa, T., Kishi, M., Ogawa, E., Tateno, F., Uchiyama, T., Yamamoto, T., Yamanishi, T., Terada, H., Sinphoni, Correlation of right frontal hypoperfusion and urinary dysfunction in inph: a spect study. Neurourol. Urodyn. 31 (2012), 50–55, 10.1002/nau.21222.
64. [64] Yin, Y., Shuke, N., Kaneko, S., Okizaki, A., Sato, J., Aburano, T., Li, Y., Mizunaga, M., Yachiku, S., Cerebral control of bladder storage in patients with detrusor overactivity. Nucl. Med. Commun. 29 (2008), 1081–1085, 10.1097/MNM.0b013e328313bc13.
65. [65] Kitta, T., Kakizaki, H., Furuno, T., Moriya, K., Tanaka, H., Shiga, T., Tamaki, N., Yabe, I., Sasaki, H., Nonomura, K., Brain activation during detrusor overactivity in patients with parkinson's disease: a positron emission tomography study. J. Urol. 175 (2006), 994–998, 10.1016/S0022-5347(05)00324-1.
66. [66] Kitta, T., Chancellor, M.B., de Groat, W.C., Shinohara, N., Yoshimura, N., Role of the anterior cingulate cortex in the control of micturition reflex in a rat model of parkinson's disease. J. Urol. 195 (2016), 1613–1620, 10.1016/j.juro.2015.11.039.
67. [67] Adler, C.H., Beach, T.G., Neuropathological basis of nonmotor manifestations of parkinson's disease. Mov. Disord. Off. J. Mov. Disord. Soc. 31 (2016), 1114–1119, 10.1002/mds.26605.
68. [68] Gelpi, E., Navarro-Otano, J., Tolosa, E., Gaig, C., Compta, Y., Rey, M.J., Marti, M.J., Hernandez, I., Valldeoriola, F., Rene, R., Ribalta, T., Multiple organ involvement by alpha-synuclein pathology in lewy body disorders. Mov. Disord. Off. J. Mov. Disord. Soc. 29 (2014), 1010–1018, 10.1002/mds.25776.
69. [69] Beach, T.G., Adler, C.H., Sue, L.I., Vedders, L., Lue, L., White, C.L. Iii, Akiyama, H., Caviness, J.N., Shill, H.A., Sabbagh, M.N., Walker, D.G., Arizona Parkinson's Disease C, Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with lewy body disorders. Acta Neuropathol. 119 (2010), 689–702, 10.1007/s00401-010-0664-3.
70. [70] VanderHorst, V.G., Samardzic, T., Saper, C.B., Anderson, M.P., Nag, S., Schneider, J.A., Bennett, D.A., Buchman, A.S., Alpha-synuclein pathology accumulates in sacral spinal visceral sensory pathways. Ann. Neurol. 78 (2015), 142–149, 10.1002/ana.24430.
71. [71] Haylen, B.T., de Ridder, D., Freeman, R.M., Swift, S.E., Berghmans, B., Lee, J., Monga, A., Petri, E., Rizk, D.E., Sand, P.K., Schaer, G.N., An international urogynecological association (iuga)/international continence society (ics) joint report on the terminology for female pelvic floor dysfunction. Int. Urogynecol. J. 21 (2010), 5–26, 10.1007/s00192-009-0976-9.
72. [72] Groen, J., Pannek, J., Castro Diaz, D., Del Popolo, G., Gross, T., Hamid, R., Karsenty, G., Kessler, T.M., Schneider, M., T Hoen, L., Blok, B., Summary of european association of urology (eau) guidelines on neuro-urology. Eur. Urol. 69 (2016), 324–333, 10.1016/j.eururo.2015.07.071.
73. [73] Swain, S., Hughes, R., Perry, M., Harrison, S., Guideline Development G, Management of lower urinary tract dysfunction in neurological disease: summary of nice guidance. BMJ, 345, 2012, e5074, 10.1136/bmj.e5074.
74. [74] Lower Urinary Tract Symptoms in Men: Management, 2015, National Institute for Health and Care Excellence.
75. [75] Urinary Incontience in Neuological Disease: Managment of Lower Urinary Tract Dysfunction in Neurological Disease. UK, 2012, National Institute for Health and Clinical Excellence.
76. [76] Vaughan, C.P., Juncos, J.L., Burgio, K.L., Goode, P.S., Wolf, R.A., Johnson, T.M. 2nd, Behavioral therapy to treat urinary incontinence in parkinson disease. Neurology 76 (2011), 1631–1634, 10.1212/WNL.0b013e318219fab3.
77. [77] Guidelines on the Clinical Investigation of Medicinal Products for the Treatment of Urinary Incontinence, 2013, European Medicines Agency.
78. [78] Aranda, B., Cramer, P., Effects of apomorphine and l-dopa on the parkinsonian bladder. Neurourol. Urodyn. 12 (1993), 203–209.
79. [79] Uchiyama, T., Sakakibara, R., Hattori, T., Yamanishi, T., Short-term effect of a single levodopa dose on micturition disturbance in parkinson's disease patients with the wearing-off phenomenon. Mov. Disord. Off. J. Mov. Disord. Soc. 18 (2003), 573–578, 10.1002/mds.10403.
80. [80] Uchiyama, T., Sakakibara, R., Yamamoto, T., Ito, T., Yamaguchi, C., Awa, Y., Yano, M., Yanagisawa, M., Kobayashi, M., Higuchi, Y., Ichikawa, T., Yamanishi, T., Hattori, T., Kuwabara, S., Comparing bromocriptine effects with levodopa effects on bladder function in parkinson's disease. Mov. Disord. Off. J. Mov. Disord. Soc. 24 (2009), 2386–2390, 10.1002/mds.22840.
81. [81] Brusa, L., Petta, F., Pisani, A., Moschella, V., Iani, C., Stanzione, P., Miano, R., Finazzi-Agro, E., Acute vs chronic effects of l-dopa on bladder function in patients with mild parkinson disease. Neurology 68 (2007), 1455–1459, 10.1212/01.wnl.0000260605.12506.86.
82. [82] Brusa, L., Musco, S., Bernardi, G., Iani, C., Pierantozzi, M., Stanzione, P., Stefani, A., Finazzi Agro, E., Rasagiline effect on bladder disturbances in early mild parkinson's disease patients. Park. Relat. Disord. 20 (2014), 931–932, 10.1016/j.parkreldis.2014.04.020.
83. [83] Christmas, T.J., Kempster, P.A., Chapple, C.R., Frankel, J.P., Lees, A.J., Stern, G.M., Milroy, E.J., Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 2 (1988), 1451–1453.
84. [84] Appell, R.A., Pharmacotherapy for overactive bladder: an evidence-based approach to selecting an antimuscarinic agent. Drugs 66 (2006), 1361–1370, 10.2165/00003495-200666100-00005.
85. [85] Blackett, H., Walker, R., Wood, B., Urinary dysfunction in parkinson's disease: a review. Park. Relat. Disord. 15 (2009), 81–87, 10.1016/j.parkreldis.2007.10.016.
86. [86] Zesiewicz, T.A., Evatt, M., Vaughan, C.P., Jahan, I., Singer, C., Ordorica, R., Salemi, J.L., Shaw, J.D., Sullivan, K.L., Non-Motor Working Group of the Parkinson Study G, Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in parkinson's disease. Park. Relat. Disord. 21 (2015), 514–520, 10.1016/j.parkreldis.2015.02.025.
87. [87] Gray, S.L., Anderson, M.L., Dublin, S., Hanlon, J.T., Hubbard, R., Walker, R., Yu, O., Crane, P.K., Larson, E.B., Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 175 (2015), 401–407, 10.1001/jamainternmed.2014.7663.
88. [88] Crispo, J.A., Willis, A.W., Thibault, D.P., Fortin, Y., Hays, H.D., McNair, D.S., Bjerre, L.M., Kohen, D.E., Perez-Lloret, S., Mattison, D.R., Krewski, D., Associations between anticholinergic burden and adverse health outcomes in parkinson disease. PloS One, 11, 2016, e0150621, 10.1371/journal.pone.0150621.
89. [89] Ehrt, U., Broich, K., Larsen, J.P., Ballard, C., Aarsland, D., Use of drugs with anticholinergic effect and impact on cognition in parkinson's disease: a cohort study. J. Neurol. Neurosurg. Psychiatry 81 (2010), 160–165, 10.1136/jnnp.2009.186239.
90. [90] Khullar, V., Amarenco, G., Angulo, J.C., Cambronero, J., Hoye, K., Milsom, I., Radziszewski, P., Rechberger, T., Boerrigter, P., Drogendijk, T., Wooning, M., Chapple, C., Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised european-australian phase 3 trial. Eur. Urol. 63 (2013), 283–295, 10.1016/j.eururo.2012.10.016.
91. [91] Ebell, M.H., Radke, T., Gardner, J., A systematic review of the efficacy and safety of desmopressin for nocturia in adults. J. Urol. 192 (2014), 829–835, 10.1016/j.juro.2014.03.095.
92. [92] Giannantoni, A., Gubbiotti, M., Bruno, R., De Vermandois, J.A.R., Nikaj, H., Proietti, S., Desmopressin in the treatment of nocturia in patients affected by neurogenic bladder. Neurourol. Urodyn. 33 (2014), S7–S8.
93. [93] Suchowersky, O., Furtado, S., Rohs, G., Beneficial effect of intranasal desmopressin for nocturnal polyuria in parkinson's disease. Mov. Disord. Off. J. Mov. Disord. Soc. 10 (1995), 337–340, 10.1002/mds.870100318.
94. [94] Nasal Formulations of Desmopressin Are No Longer Indicated for Primary Nocturnal Enuresis, 2007, Medicines and Healthcare Products Regulatory Agency, 1.
95. [95] US Food and Drug Administration, Information for Healthcare Professionals: Desmopressin Acetate (Marketed as Ddavp Nasal Spray, Ddavp Rhinal Tube, Ddavp, Ddvp, Minirin, and Stimate Nasal Spray). 2007.
96. [96] National Institute for Health and Care Excellence, Nocturia and Nocturnal Polyuria in Men with Lower Urinary Tract Symptoms: Oral Desmopressin. 2013.
97. [97] Gomes, C.M., Sammour, Z.M., Bessa Junior, J., Barbosa, E.R., Lopes, R.I., Sallem, F.S., Trigo-Rocha, F.E., Bruschini, H., Nitti, V.W., Srougi, M., Neurological status predicts response to alpha-blockers in men with voiding dysfunction and parkinson's disease. Clin. Sao Paulo 69 (2014), 817–822, 10.6061/clinics/2014(12)05.
98. [98] Anderson, R.U., Orenberg, E.K., Glowe, P., Onabotulinumtoxina office treatment for neurogenic bladder incontinence in parkinson's disease. Urology 83 (2014), 22–27, 10.1016/j.urology.2013.09.017.
99. [99] Giannantoni, A., Conte, A., Proietti, S., Giovannozzi, S., Rossi, A., Fabbrini, G., Porena, M., Berardelli, A., Botulinum toxin type a in patients with parkinson's disease and refractory overactive bladder. J. Urol. 186 (2011), 960–964, 10.1016/j.juro.2011.04.071.
100. [100] Kulaksizoglu, H., Parman, Y., Use of botulinim toxin-a for the treatment of overactive bladder symptoms in patients with parkinsons's disease. Park. Relat. Disord. 16 (2010), 531–534, 10.1016/j.parkreldis.2010.06.006.
101. [101] Staskin, D.S., Vardi, Y., Siroky, M.B., Post-prostatectomy continence in the parkinsonian patient: the significance of poor voluntary sphincter control. J. Urol. 140 (1988), 117–118.
102. [102] Roth, B., Studer, U.E., Fowler, C.J., Kessler, T.M., Benign prostatic obstruction and parkinson's disease–should transurethral resection of the prostate be avoided?. J. Urol. 181 (2009), 2209–2213, 10.1016/j.juro.2009.01.049.